ATR240816C155000
- 4.20
- 0.000.00%
AptarGroup Newsroom
AptarGroup Analyst Ratings
BofA Securities Adjusts Price Target on AptarGroup to $163 From $160
Analysts Offer Insights on Healthcare Companies: AptarGroup (ATR), Dexcom (DXCM) and Aldeyra Therapeutics (ALDX)
AptarGroup Analyst Ratings
Analysts Conflicted on These Healthcare Names: AptarGroup (ATR) and Community Health (CYH)
AptarGroup's Strong Q1 Performance and Robust Pharmaceutical Growth Justify Buy Rating
AptarGroup Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Arcellx Inc (ACLX), Sarepta Therapeutics (SRPT) and AptarGroup (ATR)
Analysts Have Conflicting Sentiments on These Healthcare Companies: AptarGroup (ATR), Halozyme (HALO) and Bausch Health Companies (BHC)
AptarGroup's Strong Performance and Growth Prospects Merit a Buy Rating
Baird Upgrades AptarGroup to Outperform, Raises Price Target to $150
AptarGroup Analyst Ratings
Hold Rating on AptarGroup Amid Modest Q3 Profits and Uncertain Q4 Outlook
Positive Financial Outlook Spurs 'Buy' Rating for AptarGroup: A Detailed Analysis of 3Q Performance and 4Q Projections
BofA Securities Adjusts Price Target on AptarGroup to $145 From $150, Maintains Buy Rating
AptarGroup (ATR) Receives a Hold From DBS
DBS Bank Starts AptarGroup at Hold Rating, $132 Price Target
AptarGroup Analyst Ratings
Wells Fargo Raises AptarGroup Price Target to $152 From $140, Maintains Overweight Rating
Analysts' Opinions Are Mixed on These Industrial Goods Stocks: Polaris (PII), CH Robinson (CHRW) and AptarGroup (ATR)